Clinical pharmacokinetics of irinotecan

Clinical Pharmacokinetics

Volumn 33, Issue 4, 1997, Pages 245-259

  Chabot, Guy G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC ALKALOID; CARBOXYLIC ACID; DNA TOPOISOMERASE; IRINOTECAN; LACTONE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER CELL DESTRUCTION; CHEMICAL STRUCTURE; COLORECTAL CANCER; DIARRHEA; DNA STRAND BREAKAGE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LIVER METABOLISM; LUNG CANCER; LYMPHOMA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; UTERINE CERVIX CANCER;

EID: 0030883212     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199733040-00001     Document Type: Review

References (114)

1. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888-90
2. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994; 54: 1431-4
3. Wall ME, Wani MC. Camptothecin and analogs: from discovery to clinic. In: Potmesil M, Pinedo H, editors. Camptothecins: new anticancer agents. Boca Raton (FL): CRC Press, Inc., 1995: 21-41
4. Wall ME, Wani MC. Camptothecin: discovery to clinic. Ann NY Acad Sci 1996; 803: 112
5. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722-6
6. Jaxel C, Kohn K, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian toopoisomerase I. Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res 1989; 49: 1465-9
7. Hsiang YH, Liu LF, Wall ME, et al. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues Cancer Res 1989; 49: 4835-9.
8. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8
9. Potmesil M, Hsiang YH, Liu LF, et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48: 3537-43
10. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-7
11. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991; 34: 98-107
12. Wani MC, Nicholas AW, Wall ME. Plant antitumor agents: 23. Synthesis and antileukemic activity of camptothecin analogues. J Med Chem 1986; 29: 2358-63
13. Hertzberg RP, Caranfa MJ, Hecht S. On the mechanism of topoisomerase 1 inhibition by eamptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989; 28: 4629-38
14. Kessel D, Bosmann HB, Lohr K. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochem Biophys Acta 1972; 269: 210-6
15. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97
16. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75
17. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38. a metabolite of the camptothecin derivative. CPT-II, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-91
18. Ogasawara H, Nishio K, Kanzawa F, et al. Intracellular carboxylesterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn J Cancer Res 1995; 86: 124-9
19. Jansen WJ, Zwaer B, Hulscher ST, et al. CPT-11 in human colon cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997; 70: 335-40
20. Suzuki A, Kato M. Chemotherapeutic agent CPT-11 induces the new expression of the apoptosis initiator to the cytoplasm. Exp Cell Res 1996; 227: 154-9
21. Woessner RD, Eng WK, Hofmann FA, et al. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 1992; 4: 481-8
22. Gupta RS, Gupta R, Eng B, et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 1988; 48: 6404-10
23. Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a camptothecin analogue (CPT-11) resistant cell line of human small cell lung cancer: characterization and mechanism of resistance. Cancer Res 1990; 50: 5919-24
24. Sugimoto Y, Tsukahara S, Oh-Hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990; 50: 6925-30
25. Tamura H, Kohchi C, Yamada R. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 1991; 51: 1129-36
26. Goldwasser F, Bae I, Valenti M, et al. Topoisonierase I-related parameters and eamptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995; 55: 2116-21
27. Chen AY, Yu C, Potmesil M, et al. Camptothecin overcomes MDRI-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51: 6039-44
28. Takeda S, Shimazoe T, Kuga H, et al. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-IN shows resistance to SN-38. an active metabolite of CPT-11. Biochem Biophys Res Commun 1992; 188: 70-7
29. Onishi Y, Oguro M, Kizaki H. A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11. Cancer Chemother Pharmacol 1997; 39: 473-8
30. Kawato Y, Furuta T, Aonuma M, et al. Antitumor activity of a camptothecin derivative. CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-8
31. Bissery MC, Vrignaud P, Lavelle F, et al. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs 1996; 7: 437-60
32. Tanizawa A, Fujimori A, Fugimori Y, et al. Comparison of topoisomcnise I inhibition. DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836-42
33. Lavelle F, Bissery MC, André S, et al. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996; 3 (1 Suppl.): 11-20
34. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993; 53: 2823-9
35. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996; 74: 537-45
36. Komuro H, Li P, Tsuchida Y, et al. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xenotransplanted neuroblastoma. Med Pediatr Oncol 1994; 23: 487-92
37. Hare CB, Elion GB, Houghton PJ, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carboxyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1997; 38: 187-91
38. Tsuruo T, Matsuzaki T, Matsushita M, et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71-4
39. Taguchi T, Wakui A, Hasegawa K. Phase I clinical study of CPT-11: Research Group of CPT-11. Jpn J Cancer Chemother 1990; 17: 115-20
40. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advance non-small cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-8
41. Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992; 84: 972-4
42. Rothenberg ML, Kuhn JG, Burris III HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194-204
43. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(4-piperidino)-1-piperidino]carbonyl-oxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-36
44. Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133-40
45. de Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-54
46. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-21
47. Gandia D, Abigerges D, Armand JP, et al. CPT-11-Induced cholinergic effects in cancer patients [letter]. J Clin Oncol 1993; 11: 196-7
48. Merrouche Y, Extra JM, Abigerges D, et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. J Clin Oncol 1997; 15: 1080-6
49. Hagipantelli R, Saliba F, Misset JL, et al. Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhoea: a prospective assessment (abstract). Proc Am Soc Clin Oncol 1995; 14: 464
50. Sakata Y, Suzuki, H, Kamataki T. Preventive effect of TJ-14, a kampo medicine, on diarrhoea induced by irinotecan hydrochloride [in Japanese]. Jpn J Cancer Chemother (Gan To Kagaku Ryoho) 1994; 21: 1241-4
51. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of -glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-7
52. Boisseau M, Guichard S, Canal P, et al. Irinotecan (CPT-11): current status and perspectives. Expert Opin Investig Drugs 1996; 5: 613-26
53. Rothenberg ML, CPT-11: an original spectrum of clinical activity. Semin Oncol 1996; 23 (1 Suppl. 3): 21-6
54. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31A: 1283-7
55. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11. a new camptothecin derivative, in inetastatic colorectal cancer: CRT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11: 909-13
56. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-15
57. Shimada Y, Rougier P, Pilot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Can 1996; 3 (32A Suppl.): S13-7
58. Rothenberg ML, Eckardt JR, Burris III HA, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-35
59. Rougier P, Bugal R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60
60. Fukuoka M, Nitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16-20
61. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225-9
62. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992; 10: 1775-80
63. Chevallier B, Lhomme C, Dieras V, et al. Phase II trial of CPT-11 in advanced cervical carcinoma [abstract]. Proc Am Soc Clin Oncol 1995; 14: 267
64. Potkul RK, Price VT, Bailey H, et al. Irinotecan (CPT-11) in advanced squamous cell carcinoma of the cervix (Phase II) (abstract). Proc Am Suc Clin Oncol 1995; 14: 279
65. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625-31
66. Sakata Y, Shimada Y, Yoshino M, et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer [in Japanese]. Gan To Kagaku Ryoho 1994; 21: 1039-46
67. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6: 129-32
68. Futatsuki K, Wakui A, Nakao I, et al. A late Phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer: CPT-11 Gastrointestinal Cancer Study Group [in Japanese). Gan To Kagaku Ryoho 1994; 21: 1033-8
69. Bonneterre J, Pion JM, Adenis A, et al. A Phase II study of a new camtothecin analog CPT-11 in previously treated advanced breast cancer patients [abstract]. Proc Am Soc Clin Oncol 1993; 12: 94
70. Taguchi T, Tominaga T, Ogawa M, et al. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer [in Japanese]. Jpn J Cancer Chemother (Gan To Kagaku Ryoho) 1994; 21: 1017-24
71. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11: a new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907-12
72. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11): CPT-11 Study Group on Hematological Malignancy. Br J Cancer 1994; 70: 771-4
73. Kaneda N, Nagata H, Furuta T, et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-20
74. Barilero I, Gandia D, Armand JP, et al. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J Chromatogr Biomed Appl 1992; 575: 275-80
75. Akimoto K, Goto A, Ohya K. Selective and sensitive determination of lactone and hydroxy acid forms of camptothecin and two derivatives (CPT-11 and SN-38) by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1991; 588: 165-70
76. Rivory LP, Robert J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr Biomed Appl 1994; 661: 133-41
77. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Appl 1997; 691: 161-71
78. Sumiyoshi H, Fujiwara Y, Ohune T, et al. High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B Biomed Appl 1995; 670: 309-16
79. Sasaki Y, Yoshida Y, Sudoh K, et al. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 1995; 86: 111-6
80. Sasaki Y, Hakusui H, Mizuno S, et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995; 86: 101-10
81. Rivory LP, Chatelut E, Canal P, et al. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 1994; 54: 6330-3
82. Tsuji T, Kaneda N, Kado K, et al. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991; 14: 341-9
83. Satoh T, Hosokawa M, Atsumi K, et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino)carbonyloxy camptothecin, a novel antitumor agent, by carboxyesterase. Biol Pharm Bull 1994; 17: 662-4
84. Rivory LP, Bowles MR, Robert J, et al. Conversion of irinotecan (CPT-11) to its active metabolite. 7-ethyl-10-hydroxycamptothecin (SN-38). by human liver carboxyesterase. Biochem Pharmacol 1996; 52: 1103-11
85. Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51
86. Rivory LP, Robert J. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995; 36: 176-9
87. Haaz MC, Rivory L, Jantet S, et al. Glucuronidation of SN-38. the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 1997; 80: 91-6
88. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhoea. Cancer Res 1994; 54: 3723-5
89. Rivory LP, Riou JF, Haaz MC, et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996; 56: 3689-94
90. Lokiec F, Monegier du Sorbier B, Sanderink GJ. Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 1996; 2: 1943-9
91. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68: 777-82
92. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony stimulating factor support for advanced lung cancer. J Clin Oncol 1994; 12: 1833-41
93. Canal P, Gay C, Dezeuze A, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996; 14: 2688-95
94. Rivory LP, Haaz MC, Canal P, et al. Pharmacokinetic inter-relationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I-II trials. Clin Cancer Res 1997; 3: 1261-6
95. Iyer L, King C, Tephly T, et al. UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan [abstract 707]. Proc Am Soc Clin Oncol 1997; 16: 201a
96. Data on file Rhône-Poulenc Rorer, S.A Antony, France
97. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994; 37: 40-6
98. Burris H, Dietz A, Eckardt J, et al. A Phase I trial to evaluate orally administered irinotecan HCI (CPT-11) given daily X 5 every 3 weeks in patients with refractory malignancies [abstract]. Proc Am Soc Clin Oncol 1996; 15: 489
99. Lokiec F, Canal P, Gay C, et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995; 36: 79-82
100. Chabot GG. Factors involved in clinical pharmacology variability in oncology. Anticancer Res 1994; 14: 2269-72
101. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15: 1502-10
102. Gupta E, Wang X, Ramirez J, et al. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997; 39: 440-4
103. Gupta E, Safa AR, Wang X, et al. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 1996; 56: 1309-14
104. Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994; 86: 1096-8
105. Grossin F, Barhault H, Benhammouda A, et al. A phase I pharmacokinetics study of concomitant CPT-11 and 5FU combination (abstract 1156). Proc Am Assoc Cancer Res 1996; 37: 168
106. Saltz LB, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996; 14: 2959-67
107. Karato A, Sasaki Y, Shiraishi J, et al. Pharmacokinetic study in the dose escalation study of CPT-11 and VP-16. [abstract]. Proc Am Assoc Cancer Res 1993; 34: 2325
108. Couteau C, Lokiec F, Vernillet L, et al. Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors [abstract 709]. Proc Am Soc Clin Oncol 1997; 16: 202a
109. Kudoh S, Fukuoka M, Masuda N, et al. Relationship between the pharmacokinetics of irinotecan and diarrhoea during combination chemotherapy wilh cisplatin. Jpn J Cancer Res 1995; 86: 406-13
110. Mick R, Gupta E, Vokes EE, et al. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 1996; 14: 2012-9
111. Chabot GG. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 1995; 36: 463-72
112. Nakashima H, Lieberman, R, Karato A, et al. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring. Ther Drug Monit 1995; 17: 221-9
113. Sasaki Y, Mizuno S, Fujii H, et al. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 1995; 86: 117-23
114. Yamamoto N, Ramura T, Karato A, et al. CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn J Cancer Res 1994; 85: 972-7